secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001937653-22-000011
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks Q3 net loss $47.8M; announces zanidatamab deal with Jazz up to $1.76B
-------------------------------------------------------------------------------

- Licensed zanidatamab to Jazz for up to $1.76B total payments plus 10-20% tiered royalties; $50M upfront expected 4Q22.
- Q3 revenue $2.6M (down from $4.4M), net loss $47.8M (vs $60.6M YoY).
- Cash $166.2M; Jazz upfront extends cash runway through at least 2026.
- Phase 1 zanidatamab zovodotin showed 31% ORR at 2.5 mg/kg Q3W; manageable tolerability.
- Aims to file 5 INDs in next 5 years; IND for ZW191 (FRα-ADC) expected 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000193765322000011/0001937653-22-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000193765322000011/zyme-20221108.htm
  HTML page:      https://secwatch.observer/filing/0001937653-22-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer